Regeneron Pharmaceuticals’ (REGN) Neutral Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report sent to investors on Friday morning, Benzinga reports. Cantor Fitzgerald currently has a $925.00 price objective on the biopharmaceutical company’s stock.

REGN has been the topic of several other reports. BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an outperform rating in a report on Monday, February 5th. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an overweight rating in a research note on Wednesday, March 13th. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an overweight rating in a research note on Tuesday, January 23rd. Truist Financial restated a buy rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an outperform rating and a $1,125.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $977.77.

Regeneron Pharmaceuticals Stock Up 2.1 %

REGN stock traded up $19.39 during trading on Friday, hitting $957.00. 547,373 shares of the company’s stock traded hands, compared to its average volume of 509,442. The firm has a market capitalization of $105.04 billion, a P/E ratio of 28.27, a PEG ratio of 2.69 and a beta of 0.17. The business has a fifty day simple moving average of $943.75 and a two-hundred day simple moving average of $896.33. The company has a quick ratio of 4.94, a current ratio of 6.40 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 1 year low of $684.80 and a 1 year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Regeneron Pharmaceuticals’s revenue was up .6% compared to the same quarter last year. During the same period last year, the company posted $10.96 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 38.86 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 854 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $979.25, for a total value of $836,279.50. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at $1,353,323.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 854 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $979.25, for a total value of $836,279.50. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at $1,353,323.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,095 shares of company stock worth $9,664,476. Company insiders own 8.83% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of REGN. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $26,000. West Paces Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the last quarter. Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $31,000. MCF Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares during the last quarter. Finally, Criterion Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $37,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.